The recall was prompted after a potentially carcinogenic impurity, N-Nitroso-N-methyl-4-aminobutyric acid, was detected in the medication, which is used to treat high blood pressure.
The drugmaker hasn’t received any reports of adverse events related to the recalled products.
Macleods is the latest drugmaker to recall its generic heart drugs over the detection of a potential carcinogen.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement